What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

This multicentric study reveals T cell remodeling and resistance factors impacting teclistamab efficacy in multiple myeloma.

To dissect immune correlates of resistance and response to teclistamab in multiple myeloma patients.
Analyzed longitudinal samples from the ResisTec trial with 100 patients treated with teclistamab.
Collected bone marrow aspirates and peripheral blood samples at various time points.
Performed single-cell RNA sequencing on immune cell populations.
Identified enrichment of myeloid-derived populations in patients with primary resistance to teclistamab.
Observed immune changes within the first month were more predictive of treatment response than baseline profiles.
Noted a failure of cytotoxic CD8⁺ T cells to expand in non-responders, indicating early immune imbalance.

Hébraud et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark